Nuevas inmunoterapias en el cáncer de vejiga no músculo-invasivo de alto riesgo: estado actual y perspectivas de futuro
- 24 August 2020
- journal article
- review article
- Published by Elsevier BV in Actas Españolas de Psiquiatría
- Vol. 44 (9), 574-585
- https://doi.org/10.1016/j.acuro.2020.06.011
Abstract
No abstract availableThis publication has 36 references indexed in Scilit:
- The prognostic significance of PD-L1 in bladder cancerOncology Reports, 2015
- Mechanism of Action of ImmunotherapySeminars in Oncology, 2014
- Mutational heterogeneity in cancer and the search for new cancer-associated genesNature, 2013
- Recurrence of high‐risk bladder cancer: A population‐based analysisCancer, 2013
- Risk of subsequent tumour recurrence and stage progression in bacille Calmette‐Guérin relapsing non‐muscle‐invasive bladder cancerBJU International, 2012
- Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring ModelJournal of Urology, 2009
- PD-1 and PD-1 ligands: from discovery to clinical applicationInternational Immunology, 2007
- PD‐L1 (B7‐H1) expression by urothelial carcinoma of the bladder and BCG‐induced granulomataCancer, 2007
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006
- Management of stage T1 tumors of the bladder: International Consensus PanelUrology, 2005